Based on the finding that the SS18-SSX fusion oncoprotein is unique to synovial sarcoma and is necessary and sufficient for tumor initiation [10], small molecules able to disrupt the SS18-SSX protein complex may have selective anti-tumor activity in synovial sarcoma. Here, SSX2 is linked to synovial sarcoma.